These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 30320649

  • 1. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
    Takeshita S, Ogawa S, Nakayama Y, Mukai N, Nakajima Y, Mizobe T, Sawa T, Tanaka KA.
    Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
    [Abstract] [Full Text] [Related]

  • 2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S.
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [Abstract] [Full Text] [Related]

  • 3. Plasma-derived factors VIIa and X mixtures (Byclot®) significantly improve impairment of coagulant potential ex vivo in plasmas from acquired hemophilia A patients.
    Ochi S, Takeyama M, Shima M, Nogami K.
    Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
    [Abstract] [Full Text] [Related]

  • 4. A Step Toward Balance: Thrombin Generation Improvement via Procoagulant Factor and Antithrombin Supplementation.
    Mitrophanov AY, Szlam F, Sniecinski RM, Levy JH, Reifman J.
    Anesth Analg; 2016 Sep; 123(3):535-46. PubMed ID: 27541717
    [Abstract] [Full Text] [Related]

  • 5. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
    Tanaka KA, Taketomi T, Szlam F, Calatzis A, Levy JH.
    Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
    [Abstract] [Full Text] [Related]

  • 6. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
    Nakatomi Y, Nakashima T, Gokudan S, Miyazaki H, Tsuji M, Hanada-Dateki T, Araki T, Tomokiyo K, Hamamoto T, Ogata Y.
    Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
    [Abstract] [Full Text] [Related]

  • 7. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
    Dickneite G, Dörr B, Kaspereit F, Tanaka KA.
    J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model.
    Mitterlechner T, Innerhofer P, Streif W, Lödl M, Danninger T, Klima G, Hansson K, Fries D.
    J Thromb Haemost; 2011 Apr; 9(4):729-37. PubMed ID: 21255250
    [Abstract] [Full Text] [Related]

  • 12. Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates.
    Caballo C, Escolar G, Diaz-Ricart M, Lopez-Vílchez I, Lozano M, Cid J, Pino M, Beltrán J, Basora M, Pereira A, Galan AM.
    Blood Transfus; 2013 Jul; 11(3):391-9. PubMed ID: 23058866
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma.
    Scharling B, Nielsen GG, Klitgaard T, Skovsted TA, Møss J, Segel S, Larsen LF.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):677-84. PubMed ID: 17890956
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic correction of thrombin generation in dilution-induced coagulopathy: computational analysis based on a data set of healthy subjects.
    Mitrophanov AY, Rosendaal FR, Reifman J.
    J Trauma Acute Care Surg; 2012 Aug; 73(2 Suppl 1):S95-S102. PubMed ID: 22847103
    [Abstract] [Full Text] [Related]

  • 17. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
    Haas T, Fries D, Velik-Salchner C, Reif C, Klingler A, Innerhofer P.
    Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
    [Abstract] [Full Text] [Related]

  • 18. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, Takedani H, Takashima Y, Matsushita T, Tawa A, Higasa S, Takata N, Sakai M, Kawakami K, Ohashi Y, Saito H.
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [Abstract] [Full Text] [Related]

  • 19. Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.
    Percy CL, Hartmann R, Jones RM, Balachandran S, Mehta D, Dockal M, Scheiflinger F, O'Donnell VB, Hall JE, Collins PW.
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):357-67. PubMed ID: 25928274
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.